Prof. Dr. med Ulrich Keilholz

CURRICULUM VITAE Prof. Dr. med Ulrich Keilholz 

Charité Comprehensive Cancer Center 

Charitéplatz 1 

D – 10117 Berlin, Germany 

born Oct. 12, 1957 in Hamm, Germany 

University education: 

1977-79 Medical School, University of Mainz, Germany (preclinical) 

1979-82 Medical School, University of Heidelberg, Germany (clinical) 

1982-83 University of Kentucky Medical School 

Scholarship from the University of Heidelberg 

1983 Final exam, University of Heidelberg, Germany, licence as a physician 

1984 Doctoral degree in clinical Medicine, University of Heidelberg, Germany, 

Clinical training: 

1983-84 Residency, University of Heidelberg, Dept. of Medicine, 

Division of Metabolism and Endocrinology 

1985-90 Residency, University of Heidelberg, Dept. of Medicine, 

Hematology, Oncology and Rheumatology. 

1987 Visiting scientist at the National Cancer Institute, 

Surgery branch (Prof. S.A. Rosenberg) 

1990 Board certification for Internal Medicine, Ärztekammer Nordbaden, Germany 

1990-97 Attending physician, University of Heidelberg, Dept. of Medicine, 

Hematology, Oncology and Rheumatology. 

1993 ‘venia legendi’ for Internal Medicine, Privatdozent 

1993 Board certification for Hematology and Medical Oncology, 

Ärztekammer Nordbaden, Germany 

since 1997 Department Vice-Chair, Dept. of Medicine III (Hematology, Oncology) Charité CBF, Berlin, Germany, Responsibility for the Medical Oncology Program 

since 1998 Professor of Medicine, Hematology and Medical Oncology 

2008 – 2012 Deputy Director, Charité Comprehensive Cancer Center 

ince 2013 Acting Director, Charité Comprehensive Cancer Center 

2015 Professorship ‘Comprehensive Oncology’ (W3) 

since 2018 Director, Charité Comprehensive Cancer Center 2 

Professional Memberships: 

EORTC Multiple Group Memberships 

Melanoma Group Chairman 2003-2005 

Head and Neck Cancer Group 

European Society of Medical Oncology (ESMO) 

Board of Directors since 2008 

American Society for Clinical Oncology (ASCO) 

Deutsche Gesellschaft für Hämatologie/Onkologie (DGHO) 

Deutsche Krebsgesellschaft, Arbeitsgemeinschaft Internistische Onkologie (AIO) 

Editorial board: Journal of Clinical Oncology 

Oral Oncology 

Journal of Immunotherapy, 

Melanoma Research 

Expert Opinion on Biological Therapy 

Journal of Translational Medicine 

Journals Lancet, J Clin Oncology, Blood, Leukemia, Cancer Research, Clinical Cancer 

Research, Oncogene, Cancer, Eur J Cancer, Br J Cancer, Intl J Cancer, 

J Clinical Apheresis, Melanoma Research, J Molecular Medicine. Int J of 

Colorectal Diseases 

Grant/ Concept review 

German Cancer Society 

Concept review, Cancer Therapy Evaluation Program (CTEB), NCI, NIH, U.S.A. 

Dutch Cancer Society 

Cancer Research UK 

Italian Research Foundation 

Multiple pharmaceutical companies, drug development strategies. 3 

Selected recent publications 

Khoja L, Lorigan P, Dive C, Keilholz U, Fusi A (2015). Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. Ann Oncol. 26(1):33-9 

Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, Vermorken JB, Kaempgen E, Durando X, Schadendorf D, Gurunath RK, Keilholz U (2014). Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol. 25(3):742-6. 

Busse A, Rapion J, Fusi A, Suciu S, Nonnenmacher A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U (2013). Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study). Cancer Immunol Immunother 62:1223-1233 

Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U (2013). Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 19:2413-2420 

Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U (2012). Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30:3810-3818. 

Fusi A, Collette S, Busse A, Suciu S, Rietz A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U (2009). Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur J Cancer 45:3189-3197. 

Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; for the EORTC Melanoma Group (2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372:117-126. 


Please feel free to share this...